Cargando…

Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies

SIMPLE SUMMARY: This review provides a roadmap to develop safe and effective OV-based future therapeutics by using several novel synthetic and system biology strategies. Integration of system and synthetic biology can improve the genetic design of OVs backbone, maintaining enough virulence-associate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tripodi, Lorella, Sasso, Emanuele, Feola, Sara, Coluccino, Ludovica, Vitale, Maria, Leoni, Guido, Szomolay, Barbara, Pastore, Lucio, Cerullo, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954314/ https://www.ncbi.nlm.nih.gov/pubmed/36831638 http://dx.doi.org/10.3390/cancers15041297

Ejemplares similares

Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma
por: Tripodi, Lorella, et al.
Publicado: (2023)

Oncolytic Adenoviruses for Cancer Therapy
por: Tripodi, Lorella, et al.
Publicado: (2021)

Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model
por: Vitale, Maria, et al.
Publicado: (2022)

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses
por: Ylösmäki, Erkko, et al.
Publicado: (2018)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site
por: Lopes, Alessandra, et al.
Publicado: (2019)

Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
por: Chiaro, Jacopo, et al.
Publicado: (2023)

Fusogenic Viruses in Oncolytic Immunotherapy
por: Krabbe, Teresa, et al.
Publicado: (2018)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021)

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity
por: Hirvinen, Mari, et al.
Publicado: (2016)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Perspectives on immunotherapy via oncolytic viruses
por: Reale, Alberto, et al.
Publicado: (2019)

Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine
por: Feola, Sara, et al.
Publicado: (2022)

Oncolytic viruses as immunotherapy: progress and remaining challenges
por: Aurelian, Laure
Publicado: (2016)

Oncolytic virus immunotherapy: future prospects for oncology
por: Raja, Junaid, et al.
Publicado: (2018)

Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
por: Yoo, So Young, et al.
Publicado: (2017)

Oncolytic Viruses: Priming Time for Cancer Immunotherapy
por: Russell, Luke, et al.
Publicado: (2019)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Rahman, Masmudur M., et al.
Publicado: (2021)

The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy
por: Zolaly, Mohammed A, et al.
Publicado: (2023)

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses
por: Hamdan, Firas, et al.
Publicado: (2023)

Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
por: Innao, Vanessa, et al.
Publicado: (2020)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus
por: Froechlich, Guendalina, et al.
Publicado: (2020)

Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform
por: Capasso, Cristian, et al.
Publicado: (2015)

High-throughput screening to enhance oncolytic virus immunotherapy
por: Allan, KJ, et al.
Publicado: (2016)

Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
por: Jhawar, Sachin R., et al.
Publicado: (2017)

Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2015)

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
por: Tian, Yaomei, et al.
Publicado: (2022)

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors
por: Li, Qingbo, et al.
Publicado: (2022)

Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
por: Omole, Richard Kolade, et al.
Publicado: (2022)

Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective
por: Muthukutty, Palaniyandi, et al.
Publicado: (2023)

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines
por: Feola, Sara, et al.
Publicado: (2022)

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
por: Gujar, Shashi, et al.
Publicado: (2018)

Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process
por: Feola, Sara, et al.
Publicado: (2020)

Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance
por: Gentile, Chiara, et al.
Publicado: (2021)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy
por: Swift, Stephanie L., et al.
Publicado: (2016)

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
por: Hamid, Omid, et al.
Publicado: (2017)

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
por: Guo, Zong Sheng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3fq2t1recbrs1kkkqjuscvdpur